Abstract
Due to their long survival and high cumulative corticosteroid dose, COPD patients become susceptible to unusual microorganisms that commonly affect immunosuppressed patients. Among them, fungi such as Aspergillus and Pneumocystis jiroveci and a bacterium Nocardia, a slow growing Gram-positive and acid-fast staining filamentous branching rod, have been reported in the last decade. Aspergillus can affect immunocompromised patients in different ways: by colonizing a cavity (aspergilloma), by local chronic invasion of lung parenchyma (chronic necrotizing aspergillosis or semi-invasive aspergillosis) or through a devastating vascular dissemination disease (invasive pulmonary aspergillosis). Nocardia is a pathogen that tends to act opportunistically, although it has also been reported in immunocompetent patients. It causes chronic lung infection, although systemic nocardiosis with or without central nervous system involvement is quite often found. Before the AIDS epidemic, Pneumocystis jiroveci (formerly known as Pneumocystis carinii f.sp. hominis) was known to affect malnourished patients. Recently it has been found colonizing chronic respiratory patients with conditions such as COPD or cystic fibrosis,but its role in the pathogenesis or evolution of COPD deterioration is unknown. The clinical presentation, diagnosis and therapeutic approach of each type of infection is discussed herein.
Keywords: Aspergillus spp, chronic necrotizing pulmonary aspergillosis (CNPA), Invasive pulmonary aspergillosis (IPA), Polyenes, Nocardia spp, Azoles
Current Respiratory Medicine Reviews
Title: Infrequent Infections in COPD
Volume: 2 Issue: 4
Author(s): Christian Domingo, M Jose Masdeu and Miguel Gallego
Affiliation:
Keywords: Aspergillus spp, chronic necrotizing pulmonary aspergillosis (CNPA), Invasive pulmonary aspergillosis (IPA), Polyenes, Nocardia spp, Azoles
Abstract: Due to their long survival and high cumulative corticosteroid dose, COPD patients become susceptible to unusual microorganisms that commonly affect immunosuppressed patients. Among them, fungi such as Aspergillus and Pneumocystis jiroveci and a bacterium Nocardia, a slow growing Gram-positive and acid-fast staining filamentous branching rod, have been reported in the last decade. Aspergillus can affect immunocompromised patients in different ways: by colonizing a cavity (aspergilloma), by local chronic invasion of lung parenchyma (chronic necrotizing aspergillosis or semi-invasive aspergillosis) or through a devastating vascular dissemination disease (invasive pulmonary aspergillosis). Nocardia is a pathogen that tends to act opportunistically, although it has also been reported in immunocompetent patients. It causes chronic lung infection, although systemic nocardiosis with or without central nervous system involvement is quite often found. Before the AIDS epidemic, Pneumocystis jiroveci (formerly known as Pneumocystis carinii f.sp. hominis) was known to affect malnourished patients. Recently it has been found colonizing chronic respiratory patients with conditions such as COPD or cystic fibrosis,but its role in the pathogenesis or evolution of COPD deterioration is unknown. The clinical presentation, diagnosis and therapeutic approach of each type of infection is discussed herein.
Export Options
About this article
Cite this article as:
Domingo Christian, Jose Masdeu M and Gallego Miguel, Infrequent Infections in COPD, Current Respiratory Medicine Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339806778777285
DOI https://dx.doi.org/10.2174/157339806778777285 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Clinical Approach to Systemic Autoinflammatory Disorders: Classification, Disease Phenotypes and Management
Current Immunology Reviews (Discontinued) Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Drug Discoveries Towards Kv1.5 Potassium Channel
Current Topics in Medicinal Chemistry Human Heart Failure: A Proteomics Perspective
Current Proteomics Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Oxidative Stress and the Pathogenesis of Atrial Fibrillation
Current Cardiology Reviews Antibodies Against Recombinant Catalytic Domain of Lethal Toxin of Clostridium sordellii Neutralize Lethal Toxin Toxicity in HeLa Cells
Protein & Peptide Letters Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Inflammation, Atrial Fibrillation and Cardiac Surgery: Current Medical and Invasive Approaches for the Treatment of Atrial Fibrillation
Current Pharmaceutical Design Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Empirical Antimicrobial Therapy and QTc Interval Prolongation in Emergency Medicine
Current Drug Safety FDG-PET in Tuberculosis
Current Molecular Imaging (Discontinued) Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in Metabolic and Related Cardiovascular Diseases
Current Molecular Pharmacology Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy